Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTC-801F in hereditary bradyarrhythmia due to KACh channelopathy
jRCT2051200061Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NTC-801F in KCNJ5-related hereditary bradyarrhythmia, sick sinus syndrome (SSS) and Atrial fibrillation (AFib) (2 arms), sponsored by Japan Agency for Medical Research and Development. Started Jan 2021; status: completed.
02
Drugs
NTC-801F
03
Conditions
KCNJ5-related hereditary bradyarrhythmiasick sinus syndrome (SSS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2051200061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200061.